Dual immune checkpoint inhibitors combined with anlotinib in the treatment of alveolar soft part sarcoma: a case report
10.12025/j.issn.1008-6358.2025.20240434
- VernacularTitle:双免疫检查点抑制剂联合安罗替尼治疗腺泡状软组织肉瘤1例报告
- Author:
Xinghua FANG
1
;
Wei LI
2
;
Yuhong ZHOU
2
Author Information
1. Department of Oncology, Shanghai Wusong Central Hospital, Shanghai 200940, China.
2. Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Publication Type:Clinicalcaseanalysis
- Keywords:
alveolar soft part sarcoma;
immune checkpoint inhibitor;
vascular inhibitor
- From:
Chinese Journal of Clinical Medicine
2025;32(1):140-144
- CountryChina
- Language:Chinese
-
Abstract:
Clinical data of a patient with alveolar soft part sarcoma (ASPS) treated at Zhongshan Hospital, Fudan University were retrospectively analyzed. The patient was initially diagnosed with abdominal ASPS with multiple lung metastases. After 6 weeks of treatment with nivolumab and ipilimumab, the patient achieved stable disease (SD). In the 7th week, the treatment was changed to a combination of nivolumab (30 mg, d1, q3w), anlotinib (8 mg, d1-14, q3w) and ipilimumab (50 mg, d1, q6w). The patient remained SD at the 12th week. The patient then underwent iliac artery embolization and intensity-modulated radiation therapy for the lesion in the psoas major muscle, while continuing the combination treatment. By the 24th week, the evaluation showed partial remission (PR) of both primary tumor and lung metastases. The patient experienced mild adverse reactions during treatment.
